Product Theaters. Light refreshments provided by the American Diabetes Association will be served to the first 300 attendees.
|
|
- Margaret Poole
- 7 years ago
- Views:
Transcription
1 Product Theaters Product Theaters, located in the rear of the Exhibit Hall, offer informative sessions focusing on particular products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. These sessions are intended for health care professionals only with practices relevant to the presented information. We regret that spouses and other guests cannot be accommodated. Light refreshments provided by the American Diabetes Association will be served to the first 300 attendees. SATURDAY, JUNE 11 12:15 p.m. 1:15 p.m. Options in Basal Insulin Basaglar (Insulin Glargine Injection) Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly USA, LLC This program will discuss an FDA-approved insulin glargine option from the Boehringer Ingelheim and Eli Lilly and Company Alliance. The presentation will provide information regarding the Basaglar clinical profile, as well as dosing and administration. Attendees will have the opportunity to ask the faculty questions about the data presented. Thomas C. Blevins, MD Endocrinologist Texas Diabetes & Endocrinology Dallas, TX 12:15 p.m. 1:15 p.m. The Role of a Once-Weekly GLP-1 RA Therapy in Improving Glucose Control Sponsored by AstraZeneca This presentation will demonstrate how glucose profiles differ amongst patients with type 2 diabetes and the opportunity to manage glucose fluctuations. The content includes a review of a study that evaluated a specific glucagon-like-peptide-1 receptor agonist (GLP-1 RA) therapy using continuous glucose monitoring (CGM) to determine its effect on 24-hour glucose control in patients with type 2 diabetes. Additionally, efficacy of this Once-Weekly GLP-1RA proven in a series of clinical trials that showed both short- and long-term efficacy will also be presented. Concluding the program will be information on the proper device preparation and administration of this Once-Weekly GLP-1 RA therapy. Helena W. Rodbard, MD, FACP, MACE Endocrine and Metabolic Consultants Rockville, MD
2 2:45 p.m. 3:30 p.m. Toujeo (Insulin Glargine Injection 300 Units/mL) A Once Daily Basal Insulin Clinical Overview and Features Toujeo (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo, including the pharmacologic profile and data from 4 EDITION clinical trials carried out in a range of adult patients with diabetes. Please see full Prescribing Information for Toujeo at the Sanofi booth 919 in the Exhibit Hall. Steven V. Edelman, MD Director, Taking Control of Your Diabetes (TCOYD ) William H. Polonsky, PhD, CDE President, Behavioral Diabetes Institute Associate Clinical Professor in Psychiatry Bruce W. Bode, MD, FACE Clinician Atlanta Diabetes Associates Atlanta, GA Deborah A. Hinnen, RN, APN, BC-ADM, CDE, FAAN, FAADE Clinician and Diabetes Educator Memorial Hospital University of Colorado Health Colorado Springs, CO 2:45 p.m. 3:30 p.m. A Once-Daily Basal Insulin Option for the Primary Care Management of Diabetes Sponsored by Novo Nordisk Inc. Discuss insulin therapy in optimizing glycemic control and long-acting basal insulin for adult patients with type 2 diabetes. Examine the efficacy and safety data of a long-acting basal insulin therapy. Describe a treatment approach that can be initiated in your adult patients with diabetes. Pablo F. Mora, MD, MSc, FACE, CDE Endocrinologist Diabetes America Plano, TX Clinical Associate Professor Division of Endocrinology University of Texas Southwestern Medical Center Dallas, TX
3 SUNDAY, JUNE 12 The Importance of Utilizing a Comprehensive Approach When Managing Patients with T2DM T2DM is a complex, progressive disease. As the number of patients with diabetes increases, it is critical to take a closer look at the ongoing challenges of getting patients to glycemic goal despite the availability of medications and detailed treatment guidelines. In this presentation, we will take a closer look at the effects of hyperglycemia prior to diabetes diagnosis, the importance of achieving individualized glycemic goals, the current diabetes treatment landscape, and finally, the potential of multifactorial approaches to treatment. Lawrence Blonde, MD, FACP, FACE Director, Ochsner Diabetes Clinical Research Unit The Frank Riddick Diabetes Institute New Orleans, LA Repatha (evolocumab) Product Overview Sponsored by Amgen Inc. The Repatha (evolocumab) mechanism of action will be reviewed, and an overview of safety data will be provided. The program will also review evidence for the efficacy of Repatha using data from phase 3 randomized, placebo controlled trials, as well as reviewing Repatha dosing and administration. A discussion of appropriate patients will be supplemented by relevant case studies. Harold E. Bays, MD, FTOS, FACC, FACE, FNLA Medical Director/President Louisville Metabolic and Atherosclerosis Research Center, Inc. Louisville, KY 12:30 p.m. 1:30 p.m. Examining Options to Go Further in the Treatment of Type 2 Diabetes Sponsored by Janssen Pharmaceuticals, Inc. This program will cover the following topics regarding a sodium-glucose co-transporter (SGLT-2) inhibitor: the role of the kidney in regulation of hyperglycemia in T2DM; the mechanism of action-mediated inhibition of SGLT-2 in the proximal convoluted tubule of the kidney; key efficacy and safety data from active-controlled clinical trials; important safety information; and a question and answer session. This program is not certified for continuing medical education. James R. Gavin III, MD, PhD Emory University School of Medicine Atlanta, GA Matthew Budoff, MD Professor of Medicine University of California, Los Angeles Torrance, CA John E. Anderson, MD Past President, Medicine & Science American Diabetes Association The Frist Clinic Nashville, TN
4 12:30 p.m. 1:30 p.m. SGLT-2 Inhibition A Glucuretic Treatment Option for Your Adult Patients With Type 2 Diabetes Sponsored by AstraZeneca The kidney has an important role in the body's regulation of glucose. In patients with type 2 diabetes, the adaptive mechanism to reabsorb glucose in the kidney is thought to become maladaptive. This program will focus on the role of sodium-glucose cotransporter-2 (SGLT-2) inhibition to reduce reabsorption of filtered glucose, lower the renal threshold for glucose, and increase urinary glucose excretion. In addition, the clinical efficacy, safety, and use of an SGLT-2 inhibitor for patients with type 2 diabetes will be reviewed. Serge Jabbour, MD, FACP, FACE Professor of Medicine Director, Division of Endocrinology, Diabetes, & Metabolic Disease Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, PA 3:00 p.m. 3:45 p.m. Toujeo (Insulin Glargine Injection 300 Units/mL) Clinical Case Studies for Starting Patients with Toujeo Toujeo (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo and to review case studies of patients staring Toujeo. Pharmacologic features of Toujeo and data from the EDITION clinical trials program will also be presented. Please see full Prescribing Information for Toujeo at the Sanofi booth 919 in the Exhibit Hall. Jeremy Pettus, MD Assistant Professor of Medicine Department of Endocrinology Timothy Gilbert, MD Practicing Endocrinologist Imperial Health Lake Charles, LA 3:00 p.m. 3:45 p.m. A Treatment Option for Patients Who Are Severely Insulin Resistant Sponsored by Lilly USA, LLC 2016 The program is about a concentrated human insulin indicated to improve glycemic control in patients with diabetes requiring >200 units of insulin a day. Hear about the product profile, patients who may benefit from it, clinical results and titration-to-target algorithms, and the dedicated injection device. Robert C. Hood, MD, FRCPC, FACE Director, Endocrine Clinic of Southeast Texas Beaumont, TX
5 MONDAY, JUNE 13 The Efficacy Mirage in Type 2 Diabetes Why Do Clinical Trial Results Disappear in Real-World Practice? Sponsored by Intarcia Therapeutics, Inc. Since 2005, nearly 40 new treatments have been approved for type 2 diabetes (T2D) with some of these agents showing impressive clinical trial efficacy. Despite this, less than half of the patient population achieves HbA1c goal, and morbidity and mortality rates are at an alarming level. Recent data have demonstrated that outcomes in the real-world fall far short of the efficacy seen in clinical trials. Adherence and persistence are key drivers behind this disconnect with current agents delivering adherence rates of less than 50% and persistence rates of less than 25% over a year. This presentation will discuss the current state of diabetes and will challenge attendees to think differently about management approaches so that in the future we can finally deliver the improved patient outcomes that we have not been able to recognize with current therapies. Steven V. Edelman, MD Director, Taking Control of Your Diabetes (TCOYD ) William H. Polonsky, PhD, CDE President, Behavioral Diabetes Institute Associate Clinical Professor in Psychiatry Rationale for an Oral Treatment for Type 2 Diabetes that Targets the Incretin Hormones Sponsored by Merck Understand the incretin effect and its impact on islet function and hepatic glucose production in T2DM. Discuss an oral treatment that targets the incretin hormones and helps to improve glycemic control in T2DM. Helena W. Rodbard, MD, FACP, MACE Endocrine and Metabolic Consultants Past President, American Association of Clinical Endocrinologists Past President, American College of Endocrinology Rockville, MD
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationNew and Future Treatments for Diabetes. Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014
New and Future Treatments for Diabetes Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014 Conflicts of interest Investigator Carmelina study of Linagliptin (Boehringer
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH.
ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH. ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationDuke Regional Diabetes Symposium 2012
Duke Regional Diabetes Symposium 2012 July 13, 2012 8:30 AM 4:30 PM North Carolina Research Campus David H. Murdock Core Laboratory Building First Floor Event Room 150 Research Campus Drive Kannapolis,
More informationCara Liday, PharmD, CDE Associate Professor, Idaho State University Clinical Pharmacist and CDE, InterMountain Medical Center Pocatello, ID The planners and presenter have disclosed no conflict of interest,
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Incretin Mimetic/Enhancer Hypoglycemics (formerly referred to as Other Hypoglycemics) A. Thresholds for Prior Authorization All prescriptions
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationLibyan International Medical University www.limu.edu.ly PBL-III. ZuhirBodalal
Libyan International Medical University www.limu.edu.ly PBL-III ZuhirBodalal Disclaimer The following is a collection of medical information from multiple sources, both online and offline. It is to be
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationAnalyzing the Global Diabetes Market 2016
Brochure More information from http://www.researchandmarkets.com/reports/2060216/ Analyzing the Global Diabetes Market 2016 Description: Diabetes is a chronic disease in which there are high levels of
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationAdvances in T2D Treatment: Elevating Management in the Primary Care Setting with New Therapeutic Options
Saturday General Session Advances in T2D Treatment: Elevating Management in the Primary Care Setting with New Therapeutic Options Charles Reasner II, MD Staff Physician, Diabetes America Adjunct Professor
More informationDOCTORS OF OSTEOPATHY Category 2 credit will be awarded for formal educational programs that are ACCME-accredited or AAFP-approved.
PHYSICIANS The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Diabetes Association
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationHow To Grow A Company
Profitability & Growth in 2006: Corporate Overview April 2006 Certain statements in this presentation may constitute forward looking statements within the meaning of the Private Securities Litigation Reform
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES
ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES Dr. Mohammad Alhadj Ali, MD, PgDip, MSc, PhD (UK) with Prof. David Owens (UK) Outline Type 1 Diabetes Immunology of Type 1 Diabetes Treatment of Type 1 Diabetes
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationGlucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results
Glucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results American Diabetes Association s 75th Scientific Sessions June 7, 2015 Boston 2 Safe Harbor Statement The following presentation
More informationIQ4I Research & Consultancy Pvt. Ltd. Type II Diabetes Mellitus Pipeline Analysis
IQ4I Research & Consultancy Pvt. Ltd. Type II Diabetes Mellitus Pipeline Analysis CONTENTS REPORT DESCRIPTION INTRODUCTION Causes & Symptoms Diagnosis Unmet needs Epidemiology Current therapies HOT TARGETS,
More informationShared Care Agreement Insulin Degludec (Tresiba )
Licensed Indication Shared Care Agreement Insulin Degludec (Tresiba ) Insulin Degludec is licensed for the treatment of diabetes mellitus in adults. Countess of Chester prescribing guidelines Restricting
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationInsulin Administration: What You Don t Know May Hurt Your Patient
Insulin Administration: What You Don t Know May Hurt Your Patient Jaime A. Davidson, MD, FACP, MACE Clinical Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Jaime A. Davidson,
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC (CO) - Insulin Delivery Systems Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Insulin Delivery Systems Client: CO Approval Date:
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationResearch to Real-World Application: Experts Weigh In on the Underuse of Anticoagulants
Publishing Staff Senior Vice President of Operations and Clinical Affairs Jeff D. Prescott, PharmD, RPh Senior Clinical Projects Manager Ida Delmendo Clinical Projects Manager Tara Petersen Project Director
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationSanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationGlucose Management University of Colorado Hospital
Glucose Management University of Colorado Hospital Bridget Everhart, MSN, NP, CDE Inpatient Diabetes Educator Bridget.Everhart@uch.edu M F Pager 303 266-7898 UCH Diabetes Program Michael McDermott MD Diabetes
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationDiscussion with Key Opinion Leaders on Educating Patients About Diabetes and the Use of Insulin
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/discussion-educating-patients-diabetes--
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationType 2 Diabetes Update For 2015
Type 2 Diabetes Update For 2015 Jerry Meece, RPh, CDE, FACA, FAADE Plaza Pharmacy and Wellness Center jmeece12@cooke.net Learning Objectives At the conclusion of this presentation, the participant will
More informationEVALUATION OF A BASAL-BOLUS INSULIN PROTOCOL FROM CONTINUING DOSING EFFICACY AND SAFETY OPTIMIZATION IN NON-CRITICALLY ILL HOSPITALIZED PATIENTS
EVALUATION OF A BASAL-BOLUS INSULIN PROTOCOL FROM CONTINUING DOSING EFFICACY AND SAFETY OPTIMIZATION IN NON-CRITICALLY ILL HOSPITALIZED PATIENTS Joanne Archer, MSN, APRN, BC-ADM, Maureen T. Greene, PhD,
More informationType 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
More informationON PENS AND NEEDLES A PRIMER ON INSULIN PENS AND PROPER INJECTION TECHNIQUES PETE KRECKEL, RPH
ON PENS AND NEEDLES A PRIMER ON INSULIN PENS AND PROPER INJECTION TECHNIQUES PETE KRECKEL, RPH ON PENS AND NEEDLES - A PRIMER ON INSULIN PENS AND PROPER INJECTION TECHNIQUES ACTIVITY DESCRIPTION Insulin
More informationNew Treatments for Type 2 Diabetes
New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust Treatments for type 2 diabetes - old & new insulin sulphonylureas
More informationAmerican Association of Clinical Endocrinologists Texas Chapter of AACE Annual Meeting and The Texas Endocrine Surgical Symposium
American Association of Clinical Endocrinologists Texas Chapter of AACE Annual Meeting and The Texas Endocrine Surgical Symposium August 5-6, 2016 Hilton Dallas Southlake Town Square 1400 Plaza Place Southlake,
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationDiabetes Treatment in a New Era: When to Begin Insulin and How to deliver it.
Diabetes Treatment in a New Era: When to Begin Insulin and How to deliver it. Objectives 1. Briefly review the evolution of insulin therapy. 2. Identify the types of insulin currently available for treatment
More informationOsteoporosis Drug Development Moving Forward Public Workshop
Osteoporosis Drug Development Moving Forward Public Workshop November 4, 2015 Discussion Panel Members and Speakers Robert Adler, MD Chief, Endocrinology and Metabolism McGuire Veterans Affairs Medical
More informationAMERICAN ASSOCIATION OF DIABETES EDUCATORS. 2014 Annual Report
AMERICAN ASSOCIATION OF DIABETES EDUCATORS 2014 Annual Report AMERICAN ASSOCIATION OF DIABETES EDUCATORS 2014 Annual Report The 2014 annual report is more than a listing of AADE s programs and partnerships
More information11TH ANNUAL DIABETES CONFERENCE JULY 24-25, 2015 CORPUS CHRISTI, TX
11TH ANNUAL DIABETES CONFERENCE JULY 24-25, 2015 CORPUS CHRISTI, TX AMERICAN BANK CENTER 1901 N. SHORELINE BLVD. Course Director: Humberto Bruschetta, M.D., F.A.C.P. COURSE OVERVIEW EDUCATIONAL NEED AND
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationNumerous studies have demonstrated that utilization
DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Supplement 2, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2015.0369 ORIGINAL ARTICLE Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among
More informationSlide 1. Diabetes care strategy. Lars Fruergaard Jørgensen EVP Corporate Development
Slide 1 Diabetes care strategy Lars Fruergaard Jørgensen EVP Corporate Development Diabetes care strategy Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationDiabetes mellitus 1 عبد هللا الزعبي. pharmacology. Shatha Khalil Shahwan. 1 P a g e
Diabetes mellitus 1 pharmacology عبد هللا الزعبي 1 P a g e 4 Shatha Khalil Shahwan Diabetes mellitus The goals of the treatment of diabetes 1. Treating symptoms 2. Treating and Preventing acute complications
More informationMerle Rosenzweig, Mark MacEachern, Anna Ercoli Schnitzer, Carrie Ashton, Gerald Abrams, Jon Crane
Merle Rosenzweig, Mark MacEachern, Anna Ercoli Schnitzer, Carrie Ashton, Gerald Abrams, Jon Crane Regents of the University of Michigan 2010 Mini Med Schools are public education programs. Typically consisting
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationThe type 2 diabetes market is undergoing a paradigm
Elsevier Business Intelligence PRESCRIPTION PHARMACEUTICALS AND BIOTECHNOLOGY July 16, 2012 Founded 1939 In A Changing Diabetes Drug Market, Who Will Come Out On Top? Jessica Merrill j.merrill@elsevier.com
More informationFRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M.
CEDARS-SINAI HYPERTENSION CENTER 2016 Clinical Highlights Symposium FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M. CONFERENCE LOCATION Harvey Morse Conference Center 8701 Gracie Allen Drive Plaza Level,
More informationBrochure More information from http://www.researchandmarkets.com/reports/3503782/
Brochure More information from http://www.researchandmarkets.com/reports/3503782/ Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and
More informationAn Interprofessional Approach to Diabetes Management
Disclosures An Interprofessional Approach to Diabetes Management Principal in DiabetesReframed, LLC. Inventor of U.S. Provisional Patent Application No. 61/585,483 METHODS OF USING A DIABETES CROSS- DISCIPLINARY
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationMonitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008
Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control Linda Macdonald, M.D. November 19, 2008 Objectives Understand the relationship between insulin, carbohydrate intake, and blood
More informationMy Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started. Combination Therapy
My Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started Combination Therapy How Can Combination Therapy Help My Type 2 Diabetes? When you have type 2 diabetes,
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More information4/23/2015. Conflict of Interest Disclosure
Endocrine/Diabetes Pharmacology Review May 8, 2015 Chris Winslow, PharmD, MBA and Amanda Brown, PharmD Conflict of Interest Disclosure A conflict of interest exists when an individual is in a position
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationThe American Diabetes Association
The American Diabetes Association and The Connecticut Alliance of Diabetes Educators Present the 43rd Annual Symposium on Diabetes For The Health Care Professional 7:30 AM 3:30 PM Wednesday, November 7,
More information3/25/11. Finding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies. Outline of Talk.
Finding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies Elaine K. Cochran, MSN, CRNP, BC-ADM National Institute of Diabetes and Digestive and Kidney Diseases
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationUse of Continuous Subcutaneous Insulin Infusion (CSII) Pumps in Hospitalized Patients Policy and Procedure
Purpose: To ensure safe and accurate administration of insulin for patients using their own external continuous subcutaneous insulin infusion pump during hospitalization. Definitions: Insulin pump: An
More informationPrediction of Kidney Disease Progression in Patients with Diabetes
Prediction of Kidney Disease Progression in Patients with Diabetes John Arthur, MD, PhD Medical University of South Carolina SEKDC Meeting September 8, 2012 Objectives Understand the importance of predicting
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationChallenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner
Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationAACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM
AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 TASK FORCE Alan J. Garber, MD, PhD, FACE, Chair Martin J. Abrahamson, MD Joshua I. Barzilay, MD, FACE Lawrence Blonde, MD, FACP, FACE Zachary T. Bloomgarden,
More informationType 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System
Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment Bruce Latham, M.D. Endocrine Specialists Greenville Health System Objectives for this presentation - Understand the thrifty genotype
More informationDrug Class Review. Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Streamlined Update 1 Report June 2014 The purpose of Drug Effectiveness Review Project reports is to make available information regarding
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationProgram All meetings are on the Convention Level unless otherwise noted.
1 Program All meetings are on the Convention Level unless otherwise noted. Wednesday, June 24, 2015 Day 1 Begin/End Time Function Meeting Room Noon 5:00 pm Attendee Arrival Registration Badge pick-up Events
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationMedical Doctor of the Clinical Research Department Sub-Investigator Centro de Investigaciones Metabólicas (CINME), Buenos Aires, Argentina.
PERSONAL INFORMATION Full Name: GUSTAVO ADOLFO LO GIÚDICE Nationality: Argentine. License Number: 108.749 UNIVERSITY DEGREES 2004-2006 Internal Medicine Specialist Hospital San Bernardino de Siena & Internal
More informationModule II Calendar of Events *This Schedule is Subject to Change*
Module II Thursday, March 22, 2012: 7:30 am Integrative Management of Hypertension and Mark Houston, M.D., MS, FACP, FAAHA Cardiovascular Disease Part One 10:00 am Integrative Management of Hypertension
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationDiabetes: Driving and the Workplace
Diabetes: Driving and the Workplace John E. Anderson, M.D. The Frist Clinic Nashville, TN Past President, Medicine and Science American Diabetes Association Presenter Disclosure Information In compliance
More information